CoLucid Pharmaceuticals (NASDAQ: CLCD) is one of 113 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare CoLucid Pharmaceuticals to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares CoLucid Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
CoLucid Pharmaceuticals N/A N/A -13.53
CoLucid Pharmaceuticals Competitors $7.79 billion $2.46 billion 0.01

CoLucid Pharmaceuticals’ competitors have higher revenue and earnings than CoLucid Pharmaceuticals. CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

CoLucid Pharmaceuticals has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, CoLucid Pharmaceuticals’ competitors have a beta of 0.87, indicating that their average stock price is 13% less volatile than the S&P 500.


This table compares CoLucid Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CoLucid Pharmaceuticals N/A -83.51% -70.62%
CoLucid Pharmaceuticals Competitors -3,194.14% -54.19% -8.28%

Analyst Recommendations

This is a summary of recent ratings and target prices for CoLucid Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CoLucid Pharmaceuticals 0 3 2 0 2.40
CoLucid Pharmaceuticals Competitors 952 3818 6060 164 2.49

CoLucid Pharmaceuticals currently has a consensus target price of $45.88, suggesting a potential downside of 1.41%. As a group, “Pharmaceuticals” companies have a potential upside of 22.86%. Given CoLucid Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts clearly believe CoLucid Pharmaceuticals has less favorable growth aspects than its competitors.


CoLucid Pharmaceuticals competitors beat CoLucid Pharmaceuticals on 7 of the 11 factors compared.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.